BridgeBio Oncology Therapeutics (BBOT) Current Assets (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Current Assets of $266.5 million for Q1 2026, down 38.37% sequentially from $432.4 million in Q4 2025, and up 21402.62% YoY from N/an in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Current Assets (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Current Assets for 3 years, with the latest figure at $266.5 million in Q1 2026.
- Quarterly Current Assets rose 21402.62% year-over-year to $266.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.5 million (up 21402.62% YoY) and the FY2025 annual result came in at $432.4 million, up 172.47% from the prior year.
- Current Assets retreated to $266.5 million in Q1 2026 per BBOT's latest filing, from $432.4 million in the prior quarter.
- Over five years, Current Assets peaked at $476.0 million in Q3 2025 and troughed at $876779.0 in Q2 2025.
- A 3-year average of $149.1 million and a median of $2.1 million in 2024 frame the typical range for Current Assets.
- The widest YoY moves for Current Assets: up 23213.22% in 2025, down 57.76% in 2025.
- Over 3 years, Current Assets stood at $158.7 million in 2024, then surged by 172.47% to $432.4 million in 2025, then slumped by 38.37% to $266.5 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $266.5 million, $432.4 million, and $476.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 242.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 242.38 Mn |
| Mar 31, 2026 | 266.50 Mn |
| Dec 31, 2025 | 432.40 Mn |
| Sep 30, 2025 | 476.01 Mn |
| Jun 30, 2025 | 876,779.00 |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 158.69 Mn |
| Sep 30, 2024 | 2.04 Mn |
| Jun 30, 2024 | 2.08 Mn |
| Mar 31, 2024 | 2.11 Mn |